New Clinical Investigation Exclusivity (3-Year Exclusivity) for Drug Products: Questions and Answers
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
March 3, 2026
March 3, 2026
19bf8380-085c-46d8-a480-d28b1c37d3de
Related Documents
Establishing Impurity Specifications for Antibiotics
Guidance DocumentApril 20, 2026Center for Drug Evaluation and Research
Sameness Evaluations in an ANDA — Active Ingredients
Guidance DocumentNovember 8, 2022Center for Drug Evaluation and Research
Evaluation of Therapeutic Equivalence
Guidance DocumentJuly 21, 2022Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox